Extending a Systems Model of the APP Pathway: Separation of β- and γ-Secretase Sequential Cleavage Steps of APP
- 1 June 2018
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 365 (3) , 507-518
Abstract
The abnormal accumulation of amyloid-β (Aβ) in the brain parenchyma has been posited as a central event in the pathophysiology of Alzheimer’s disease. Recently, we have proposed a systems pharmacology model of the amyloid precursor protein (APP) pathway, describing the Aβ APP metabolite responses (Aβ40, Aβ42, sAPPα, and sAPPβ) to β-secretase 1 (BACE1) inhibition. In this investigation this model was challenged to describe Aβ dynamics following γ-secretase (GS) inhibition. This led an extended systems pharmacology model, with separate descriptions to characterize the sequential cleavage steps of APP by BACE1 and GS, to describe the differences in Aβ response to their respective inhibition. Following GS inhibition, a lower Aβ40 formation rate constant was observed, compared with BACE1 inhibition. Both BACE1 and GS inhibition were predicted to lower Aβ oligomer levels. Further model refinement and new data may be helpful to fully understand the difference in Aβ dynamics following BACE1 versus GS inhibition.Keywords
This publication has 22 references indexed in Scilit:
- CNS Amyloid- , Soluble APP- and - Kinetics during BACE InhibitionThe Journal of Neuroscience, 2014
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's DiseaseNew England Journal of Medicine, 2013
- BMS-708,163 Targets Presenilin and Lacks Notch-Sparing ActivityBiochemistry, 2012
- The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothesNature Neuroscience, 2012
- Acute γ-Secretase Inhibition of Nonhuman Primate CNS Shifts Amyloid Precursor Protein (APP) Metabolism from Amyloid-β Production to Alternative APP Fragments without Amyloid-β ReboundJournal of Neuroscience, 2010
- Modeling Effect of a γ-Secretase Inhibitor on Amyloid-β Dynamics Reveals Significant Role of an Amyloid Clearance MechanismBulletin of Mathematical Biology, 2010
- Present and prospective clinical therapeutic regimens for Alzheimer’s diseaseNeuropsychiatric Disease and Treatment, 2008
- The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers DiseaseCurrent Genomics, 2007
- A Portrait of Alzheimer Secretases--New Features and Familiar FacesScience, 2001
- Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)Neuron, 1994